Advertisement

Topics

Merck and AstraZeneca to develop and market lynparza for multiple cancer treatments

19:00 EDT 30 Jul 2017 | Pharmaceutical Technology

Merck has entered a global strategic oncology collaboration to jointly develop and commercialise AstraZeneca’s lynparza (olaparib) for the treatment of multiple cancer types.

Original Article: Merck and AstraZeneca to develop and market lynparza for multiple cancer treatments

NEXT ARTICLE

More From BioPortfolio on "Merck and AstraZeneca to develop and market lynparza for multiple cancer treatments"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...